Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Enlivex Therapeutics (Nasdaq: ENLV) has initiated a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange with the last TASE trading day expected to be April 23, 2026 and delisting effective on or about April 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enlivex Therapeutics (Nasdaq: ENLV) has initiated a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange with the last TASE trading day expected to be April 23, 2026 and delisting effective on or about April 26, 2026. The company will continue to trade on Nasdaq under the symbol ENLV and will keep filing public reports with the SEC and Nasdaq.
The board approved the move to operate under a single set of listing requirements, reduce duplicative administrative costs, potentially enhance Nasdaq liquidity, and focus investor relations on U.S. capital markets.
Positive
- Transition to single listing on Nasdaq to simplify compliance requirements
- Objective to reduce duplicative administrative costs
- Potential to enhance liquidity on Nasdaq by concentrating trading
Negative
- TASE delisting may reduce direct trading access for some Israeli investors
- Share transfers from TASE to Nasdaq could create short-term administrative friction for holders
Details
News Market Reaction – ENLV
On Jan 23, the day this news came out, ENLV closed 2.86% above the previous close.
Data tracked by StockTitan Argus for the Jan 23 session.
Key Figures
- Par value
- NIS 0.40 per share
- Ordinary shares as described in delisting announcement
- Last TASE trading day
- April 23, 2026
- Final day ENLV ordinary shares trade on TASE
- TASE delisting date
- On or about April 26, 2026
- Expected date ordinary shares delist from TASE
- Current share price
- $1.05
- Price prior to delisting news impact assessment
- Price change 24h
- 7.03%
- Move on day of TASE delisting announcement
- Volume today
- 583,572 shares
- Compared to 20-day average volume
- 52-week high
- $2.10
- Upper end of 52-week trading range
- 52-week low
- $0.66
- Lower end of 52-week trading range
Historical Context
-
RAIN token began trading on KuCoin, expanding access and liquidity.
-
Fireside chat on $212M raise, RAIN strategy, and Allocetra development.
-
Closing of $212M private placement to fund RAIN-focused treasury plan.
-
$212M private placement and Matteo Renzi joining the board.
-
$212M PIPE to fund RAIN token treasury and Allocetra program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
Tel Aviv Stock Exchange financial
Nasdaq Capital Market financial
U.S. Securities and Exchange Commission regulatory
par value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing
Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initiated a process to voluntarily delist its ordinary shares, par value NIS 0.40 per share, from the Tel Aviv Stock Exchange (the “TASE”).
In accordance with applicable Israeli law and the rules of the TASE, the last day the ordinary shares will trade on the TASE is expected to be April 23, 2026, and the ordinary shares are expected to be delisted from the TASE on or about April 26, 2026. Shareholders will be able to continue to buy and sell ordinary shares on the TASE in the same manner as has been the case to date until market close on the final day of trading.
The Company's ordinary shares will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ENLV," and the Company will also continue to file public reports and disclosures in accordance with the rules and regulations promulgated by the U.S. Securities and Exchange Commission (“SEC”) and Nasdaq. The delisting from the TASE will not affect Enlivex’s continued listing on Nasdaq in the United States, and all ordinary shares currently traded on the TASE may be transferred to Nasdaq.
The Company’s Board of Directors approved the delisting of the ordinary shares from the TASE and a transition to exclusive trading on Nasdaq with the objective of operating under a single set of listing requirements, reducing duplicative administrative costs, potentially enhancing liquidity on Nasdaq, and allowing the Company to focus its investor and public relations efforts on the U.S. capital markets.
About Enlivex Therapeutics
Enlivex is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra™, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, Enlivex is the first publicly-listed company to have developed a treasury strategy centered on RAIN, which currently serves as the primary treasury reserve asset of the Company. In adopting its treasury policy, Enlivex intends to provide investors with exposure to RAIN and to advocate for its role as digital capital.
With respect the Company’s clinical development focus, osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the Company’s voluntary delisting from the TASE, the last date the Company’s ordinary shares will trade on the TASE and the date the ordinary shares will be delisted from the TASE; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.
Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.no obligation to update or revise any of these statements, except as required by applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivex.com
INVESTOR RELATIONS CONTACT
KCSA Strategic Communications
Jack Perkins
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.